Global /United States /Healthcare /Biotechnology /CRMD

CorMedix Inc.

CRMD

• NASDAQ: CRMD • Delayed

7.48USD -1.2%

As of 16 June 2026, CorMedix Inc. has a market cap of $586.64M USD, ranking #14106 globally and #2530 in the United States. It ranks #1255 in the Healthcare sector, and #235 in the Biotechnology industry.

Global Rank

14106

Country Rank

2530

Sector Rank

1255

Industry Rank

235

Key Stats

Market Cap

$586.64MUSD

Enterprise Value

$576.66MUSD

Revenue (TTM)

$311.71MUSD

EBITDA (TTM)

$174.89MUSD

Net Income (TTM)

$162.07MUSD

EBITDA Margin

56%

Profit Margin

52%

PE Ratio

3.7

Forward PE

13.4

PS Ratio

1.9

PB Ratio

1.5

EV/EBITDA

3.3

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Joseph Todisco open_in_new

Employees

191

Founded

2006

IPO

25 Mar 2010

Website

cormedix.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.2%	-0.1%	11%	-3.5%	-33%	-36%	-17%	51%	-15%

News

CRMD Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	CRMD Cormedix Inc ISIN: US21900C3088 Shares Out.: Shares Outstanding: 78.452M¹ Shares Float: 72.267M² TV: TradingView: NASDAQ: CRMD SA: Stock Analysis: NASDAQ: CRMD YF: Yahoo Finance: CRMD GF: Google Finance: NASDAQ: CRMD NQ: NASDAQ: CRMD BA: Barron's: CRMD MS: Morningstar: XNAS: CRMD	7.48 USD	TV: TradingView: NASDAQ: CRMD SA: Stock Analysis: NASDAQ: CRMD YF: Yahoo Finance: CRMD GF: Google Finance: NASDAQ: CRMD NQ: NASDAQ: CRMD BA: Barron's: CRMD MS: Morningstar: XNAS: CRMD
Frankfurt Stock Exchange (FRA) MIC: XFRA	19KA Cormedix Inc ISIN: US21900C3088 TV: TradingView: FWB: 19KA SA: Stock Analysis: FRA: 19KA YF: Yahoo Finance: 19KA.F GF: Google Finance: FRA: 19KA BA: Barron's: 19KA MS: Morningstar: XFRA: 19KA	6.28 EUR	TV: TradingView: FWB: 19KA SA: Stock Analysis: FRA: 19KA YF: Yahoo Finance: 19KA.F GF: Google Finance: FRA: 19KA BA: Barron's: 19KA MS: Morningstar: XFRA: 19KA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About CorMedix Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 31K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 27K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 5K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 4K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 4K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 3K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.99B 41.39B EUR 8K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$45.02B 68.19T KRW 8K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.64B 60.27B AUD 7K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.46B 33.71B CHF 7K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.23B 42.76T KRW 5K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 4K%	-	Germany

chevron_leftBack